According to a joint statement from BioNTech and CEPI, the collaboration involves the development of mRNA-based vaccines against the Mpox virus (monkeypox), which causes skin rashes and can be transmitted to humans through physical contact.

According to the statement, CEPI will provide BioNTech with up to 90 million dollars in funding for the development of vaccines.